maravai lifesciences holdings glp-1 receptor agonist medications Market Size & Analysis, 2026-2033 Current Perspectives on GLP-1 Agonists

Semaglutide GLP-1 (Wegovy): Semaglutide GLP-1 is available as a weekly injectable option that many patients find convenient

Pramlintide is an amylin analogue licensed for type 1 diabetes in the US but currently very few people are treated with it [4], and the risk of severe hypoglycaemia remains a barrier to its approval in the UK and Europe [5]

GLP-1RAs exert their effects by stimulating insulin secretion, suppressing glucagon release, delaying gastric emptying, and reducing appetite through the activation of the GLP-1 receptor

It is the first triple-hormone receptor agonist targeting GLP-1, GIP, and glucagon receptors simultaneously, a mechanism that produced 24.2% mean body weight reduction in Phase 2 trials and a staggering 28.7% in Phase 3 data

Coupled with healthy eating and keeping active, people with diabetes have the opportunity to improve their health and quality of life with this novel medication class